TY - JOUR
T1 - Alterations in Spinal Cord Metabolism during Treatment of Neuropathic Pain
AU - Johnson, Caroline H.
AU - Patti, Gary J.
AU - Courade, Jean Philippe
AU - Shriver, Leah P.
AU - Hoang, Linh T.
AU - Manchester, Marianne
AU - Siuzdak, Gary
N1 - Funding Information:
This work was supported by US National Institutes of Health grants R01 CA170737 (G.S.), P30 MH062261 (G.S.), RC1 HL101034 (G.S.), P01 DA026146 (G.S.).
Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/9/22
Y1 - 2015/9/22
N2 - Therapeutic options for neuropathic pain have improved over the last 20 years yet still only provide partial relief with numerous side effects. Recently, metabolomics revealed that the concentration of the endogenous metabolite N,N-dimethylsphingosine (DMS) is increased in the spinal cord in a model of neuropathic pain. Additionally, it was shown that introduction of DMS to the central nervous system (CNS) resulted in mechanical allodynia. Here, we have examined two compounds; pregabalin (Lyrica®), a drug used to treat neuropathic pain, and N-oleoylethanolamine (NOE), an endogenous endocannabinoid-like compound that is known to affect multiple lipid pathways. We found that the concentration of DMS in the spinal cord was not significantly altered upon pregabalin treatment of rats suffering from neuropathic pain. We further explored whether modulating lipid metabolism may impact neuropathic pain by testing NOE as a potential novel therapeutic.
AB - Therapeutic options for neuropathic pain have improved over the last 20 years yet still only provide partial relief with numerous side effects. Recently, metabolomics revealed that the concentration of the endogenous metabolite N,N-dimethylsphingosine (DMS) is increased in the spinal cord in a model of neuropathic pain. Additionally, it was shown that introduction of DMS to the central nervous system (CNS) resulted in mechanical allodynia. Here, we have examined two compounds; pregabalin (Lyrica®), a drug used to treat neuropathic pain, and N-oleoylethanolamine (NOE), an endogenous endocannabinoid-like compound that is known to affect multiple lipid pathways. We found that the concentration of DMS in the spinal cord was not significantly altered upon pregabalin treatment of rats suffering from neuropathic pain. We further explored whether modulating lipid metabolism may impact neuropathic pain by testing NOE as a potential novel therapeutic.
KW - Antimetabolite
KW - Metabolomics
KW - N,N-dimethylsphingosine
KW - N-oleoylethanolamine
KW - Neuropathic pain
KW - Pregabalin
UR - http://www.scopus.com/inward/record.url?scp=84939572715&partnerID=8YFLogxK
U2 - 10.1007/s11481-015-9624-y
DO - 10.1007/s11481-015-9624-y
M3 - Article
C2 - 26232265
AN - SCOPUS:84939572715
SN - 1557-1890
VL - 10
SP - 396
EP - 401
JO - Journal of Neuroimmune Pharmacology
JF - Journal of Neuroimmune Pharmacology
IS - 3
ER -